CL2013002938A1 - Composicion farmaceutica solida que comprende ec145 (vintafolida) y un agente de volumen; metodo para producir esta composicion farmaceutica liofilizada que comprende opcionalmente un tampon; producto farmacologico; unidad de dosificacion; y metodo para tratar un tumor portador de receptores de folato funcionalmente activos. - Google Patents

Composicion farmaceutica solida que comprende ec145 (vintafolida) y un agente de volumen; metodo para producir esta composicion farmaceutica liofilizada que comprende opcionalmente un tampon; producto farmacologico; unidad de dosificacion; y metodo para tratar un tumor portador de receptores de folato funcionalmente activos.

Info

Publication number
CL2013002938A1
CL2013002938A1 CL2013002938A CL2013002938A CL2013002938A1 CL 2013002938 A1 CL2013002938 A1 CL 2013002938A1 CL 2013002938 A CL2013002938 A CL 2013002938A CL 2013002938 A CL2013002938 A CL 2013002938A CL 2013002938 A1 CL2013002938 A1 CL 2013002938A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
vintafolida
buffer
treating
producing
Prior art date
Application number
CL2013002938A
Other languages
English (en)
Inventor
Allen Ritter
Amy C Williams
Lars Waldmann
Huamin Zhang
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CL2013002938A1 publication Critical patent/CL2013002938A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013002938A 2011-04-12 2013-10-11 Composicion farmaceutica solida que comprende ec145 (vintafolida) y un agente de volumen; metodo para producir esta composicion farmaceutica liofilizada que comprende opcionalmente un tampon; producto farmacologico; unidad de dosificacion; y metodo para tratar un tumor portador de receptores de folato funcionalmente activos. CL2013002938A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161474428P 2011-04-12 2011-04-12

Publications (1)

Publication Number Publication Date
CL2013002938A1 true CL2013002938A1 (es) 2014-08-22

Family

ID=47009691

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002938A CL2013002938A1 (es) 2011-04-12 2013-10-11 Composicion farmaceutica solida que comprende ec145 (vintafolida) y un agente de volumen; metodo para producir esta composicion farmaceutica liofilizada que comprende opcionalmente un tampon; producto farmacologico; unidad de dosificacion; y metodo para tratar un tumor portador de receptores de folato funcionalmente activos.

Country Status (15)

Country Link
US (1) US20140030321A1 (es)
EP (1) EP2696684A4 (es)
JP (1) JP2014510791A (es)
KR (1) KR20140022879A (es)
CN (1) CN103607891A (es)
AU (1) AU2012242820A1 (es)
BR (1) BR112013026352A2 (es)
CA (1) CA2832858A1 (es)
CL (1) CL2013002938A1 (es)
EA (1) EA201391512A1 (es)
IL (1) IL228742A0 (es)
MX (1) MX2013011767A (es)
SG (1) SG194458A1 (es)
WO (1) WO2012142281A1 (es)
ZA (1) ZA201308414B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113359A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
US20140199286A1 (en) * 2013-01-15 2014-07-17 Teva Pharmaceutical Industries, Ltd. Lyophilization process

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512475A (ja) * 1999-10-27 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体の塩形態
NZ541846A (en) * 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US8697661B2 (en) * 2009-06-24 2014-04-15 Christine Kritikou Use of spinosyns and spinosyn compositions against herpesviridae viral infections
AU2010278734A1 (en) * 2009-07-31 2012-02-23 Endocyte, Inc. Folate-targeted diagnostics and treatment

Also Published As

Publication number Publication date
US20140030321A1 (en) 2014-01-30
IL228742A0 (en) 2013-12-31
ZA201308414B (en) 2015-05-27
EP2696684A1 (en) 2014-02-19
CN103607891A (zh) 2014-02-26
KR20140022879A (ko) 2014-02-25
JP2014510791A (ja) 2014-05-01
BR112013026352A2 (pt) 2016-07-26
EP2696684A4 (en) 2014-11-05
AU2012242820A1 (en) 2013-04-18
MX2013011767A (es) 2013-11-01
WO2012142281A1 (en) 2012-10-18
CA2832858A1 (en) 2012-10-18
EA201391512A1 (ru) 2014-05-30
SG194458A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
IL285474A (en) Anti- pdl1 antibody compositions
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
HK1200187A1 (en) Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
IL222012A (en) Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BR112014015003A2 (pt) composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BR112013014203A2 (pt) peptídeo anfifílico bicéfalo, hidrogel e método para liberação de um agente bioativo
CL2008000719A1 (es) Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
BR112013010102A2 (pt) microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal
CL2013000237A1 (es) Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.
BRPI1003991A2 (pt) métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento
BRPI1007334A2 (pt) composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.
GB201014391D0 (en) Drug composition and its use in therapy
CL2013002938A1 (es) Composicion farmaceutica solida que comprende ec145 (vintafolida) y un agente de volumen; metodo para producir esta composicion farmaceutica liofilizada que comprende opcionalmente un tampon; producto farmacologico; unidad de dosificacion; y metodo para tratar un tumor portador de receptores de folato funcionalmente activos.